Evaluation of anti-lived and anti-fixed Leishmania ( Viannia ) braziliensis promastigote IgG antibodies detected by flow cytometry for diagnosis and post-therapeutic cure assessment in localized cutaneous leishmaniasis

• Published in: Diagnostic microbiology and infectious disease 2012-11, Vol.74 (3), p.292-298
• Main Authors: Pereira, Valéria Rêgo Alves, Reis, Luiza de Campos, Souza, Marina de Assis, de Oliveira, Andresa Pereira, de Brito, Maria Edileuza Felinto, Lage, Patrícia S, Andrade, Mariléia Chaves, Rocha, Roberta Dias Rodrigues, Martins-Filho, Olindo Assis
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Protozoan - blood; Antiprotozoal Agents - administration & dosage; Biological and medical sciences; Drug Monitoring - methods; FC-AFPA; FC-ALPA; Female; Flow cytometry; Flow Cytometry - methods; Fundamental and applied biological sciences. Psychology; Humans; IgG; Immunoglobulin G - blood; Infectious Disease; Infectious diseases; Internal Medicine; L. (V.) braziliensis; Leishmania braziliensis - immunology; Leishmaniasis, Cutaneous - diagnosis; Leishmaniasis, Cutaneous - drug therapy; Leishmaniasis, Cutaneous - immunology; Life cycle. Host-agent relationship. Pathogenesis; Localized cutaneous leishmaniasis; Male; Medical sciences; Microbiology; Middle Aged; Protozoa; Treatment Outcome; Young Adult
• ISSN: 0732-8893; 1879-0070
• DOI: 10.1016/j.diagmicrobio.2012.06.025

Abstract This study aims to investigate a flow cytometry performance–based methodology to detect anti-live (FC-ALPA-IgG) and anti-fixed (FC-AFPA-IgG) Leishmania ( Viannia ) braziliensis promastigote IgG as a means to monitor post-therapeutic cure of patients with localized cutaneous leishmaniasis (LCL). Serum samples from 30 LCL patients infected with L. (V.) braziliensis were assayed, comparing the IgG reactivity before and after specific treatment with pentavalent antimonial. Reactivities were reported as the percentage of positive fluorescent parasites (PPFP), using a PPFP of 60% as a cut-off value. In the serum dilution of 1:1024, the positive percentage of LCL serum sample for FC-ALPA-IgG and FC-AFPA-IgG was 86% and 90%, respectively, before treatment. Analysis of ∆PPFP that represents the difference between PPFP after and before treatment appeared as a new approach to monitor post-therapeutic IgG reactivity in LCL. Our data support the perspective of using FC-ALPA and FC-AFPA as a useful serologic tool for diagnosis and for post-therapeutic follow-up of LCL patients.